Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Nov
22
Today In Oncology
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women
Large AI Breast Cancer Screening Trial Increases Detection Rate
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo